Browsing by Author "Servitja Tormo, Sonia"

Sort by: Order: Results:

  • Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Rial, Abora; Cos, Maria Lourdes; Campodarve, Isabel; Rodriguez-Morera, Jaime; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Springer, 2019)
    PURPOSE: The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and their adherence to the treatment. This study evaluates the ...
  • Posso, Margarita; Corominas Torres, Josep Maria; Serrano, Laia; Román, Marta; Torá Rocamora, Isabel, 1979-; Domingo, Laia; Romero, Anabel; Quintana, María Jesús; Vernet-Tomás, Maria; Baré, Marisa; Vidal, Carmen; Sánchez, Mar; Saladié, Francina; Natal, Carmen; Ferrer, Joana; Servitja Tormo, Sonia; Sala, Maria; Castells, Xavier; BELE Study Group (Wiley, 2017)
    Women with benign breast diseases (BBD) have a high risk of breast cancer. However, no biomarkers have been clearly established to predict cancer in these women. Our aim was to explore whether estrogen receptor (ER), ...
  • Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Casamayor, Guillem; Cos, Maria Lourdes; Rial, Abora; Rodriguez-Morera, Jaime; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information about bone mineral density (BMD) after completing AI-treatment. The ...
  • Román, Marta; Caicoya, Martin; Espinàs, Josep Alfons; Sala Serra, Maria; Torá Rocamora, Isabel, 1979-; Quinta, Maria J.; Vernet-Tomás, Maria; Saladié, Francina; Romero, Anabel; Sánchez, Mar; Baré, Marisa; Vidal, Carmen; Servitja Tormo, Sonia; Natal, Carmen; Corominas Torres, Josep Maria; Ferrer, Joana; Rodríguez Arana, Ana Maria; Castells, Xavier; BELE Study Group (Wiley-Blackwell, 2018)
    Women with a benign breast disease (BBD) have an increased risk of subsequent breast carcinoma. Information is scarce regarding the characteristics of breast carcinomas diagnosed after a BBD. Our aim was to point out the ...
  • Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (Impact Journals, 2014)
    NF-кB has been linked to doxorubicin resistance in breast cancer patients. NF-кB nuclear translocation and DNA binding in doxorubicin treated-breast cancer cells have been extensively examined; however its functional ...
  • Rodríguez Sanz, Maria, 1984-; Prieto-Alhambra, Daniel; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Garrigos, L.; Albanell Mestres, Joan; Martinez-García, Maria; González, I.; Martos, Tamara; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Nogués Solan, Francesc Xavier (Sociedad Española de Investigación Ósea y del Metabolismo Mineral, 2015)
    Objetivos: El objetivo del estudio fue analizar los cambios en la densidad mineral ósea (DMO) a lo largo del tratamiento con inhibidores de aromatasa (IA) en la práctica clínica y evaluar la asociación entre el gen CYP11A1 ...
  • Pineda-Moncusí, Marta; Garcia Giralt, Natàlia; Díez Pérez, Adolfo; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Prieto-Alhambra, Daniel; Nogués Solan, Francesc Xavier (Wiley, 2020)
    Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteoporotic fractures. Currently, bisphosphonates are recommended to reduce fracture risk in these patients. The aim of this ...
  • Muntasell i Castellví, Aura, 1972-; Cabo, Mariona; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Ayala de la Peña, F.; Andrés, R.; Garcia-Saenz, José Angel; Manso, Luis; Margeli, M. E.; Dalmau, M. E.; Pernas, S.; Prat, Aleix; Servitja Tormo, Sonia; Ciruelos, Eva (SpringerOpen, 2019)
    Breast cancer is the most common cancer in women in our country and it is usually diagnosed in the early and potentially curable stages. Nevertheless, around 20-30% of patients will relapse despite appropriate locoregional ...
  • Garcia-Saenz, José Angel; Bermejo, Begoña; Estevez, L. G.; Palomo, A. G.; González-Farré, X.; Margeli, M. E.; Pernas, S.; Servitja Tormo, Sonia; Rodríguez, C. A.; Ciruelos, Eva (Springer, 2015)
    Breast cancer is a major public health problem. Despite remarkable advances in early diagnosis and treatment, one in three women may have metastases since diagnosis. Better understanding of prognostic and predictive factors ...
  • Rodríguez Sanz, Maria, 1984-; Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Martos, Tamara; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rodriguez-Morera, Jaime; Díez Pérez, Adolfo; Albanell Mestres, Joan; Nogués Solan, Francesc Xavier (Elsevier, 2016)
    INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. ...
  • Dierssen Sotos, Trinidad; Servitja Tormo, Sonia; Gracia Lavedan, Esther; Castaño Vinyals, Gemma; Kogevinas, Manolis; Llorca, Javier (BioMed Central, 2016)
    Background: The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported ...
  • Pineda-Moncusí, Marta; García-Pérez, Miguel Angel; Rial, Abora; Casamayor, Guillem; Cos, Maria Lourdes; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Díez Pérez, Adolfo; Cano, Antonio; Garcia Giralt, Natàlia; Nogués Solan, Francesc Xavier (Elsevier, 2018)
    To evaluate the vitamin D status of postmenopausal women with early estrogen-receptor-positive breast cancer and to compare it with that of healthy postmenopausal women from the same Mediterranean region. STUDY DESIGN AND ...